Blue Jet Healthcare’s Q1 FY27 revenue hit INR293 Cr (+25% QoQ), with EBITDA at INR98 Cr (33.5% margin). PI segment drove growth; contrast media sales saw INR30 Cr higher goods in transit.

Gross margins faced raw material price pressure, but operating EBITDA improved with sales.

Strategic projects are on track: Vizag expansion (INR1,000 Cr over 3 years, INR250 Cr in FY27) for multiple platforms; Hyderabad R&D for advanced chemistry (peptides, GLP-1) soon operational; and Unit 3 backward integration contributing by H2 FY27. Management sees strong PI-API visibility & 4 chronic therapy NCE programs advancing.

The outlook indicates confident long-term growth.